|
In Hyderabad Next Week
|
|
3
|
241
|
August 20, 2026
|
|
From Detection to Prediction: AI-driven Process Analytical Technology for Nitrosamine and NDSRI Control in Pharmaceuticals-Pub
|
|
0
|
185
|
August 19, 2026
|
|
A Rapid and Sensitive LC–MS/MS Method for Quantification of NDSRI in Melatonin Drug Product via Controlled In Situ Formation-Pub
|
|
0
|
156
|
August 14, 2026
|
|
The TGA updated information for acceptable intake of nitrosamine impurities in medicines on 14 August 2026
|
|
0
|
525
|
August 14, 2026
|
|
N-Nitroso Metamizole Impurity C
|
|
5
|
601
|
August 11, 2026
|
|
An Analytical Quality by Design-guided method development for the quantification of N-nitroso-fluoxetine to support mitigation strategies for a fluoxetine drug product-Pub
|
|
2
|
296
|
August 8, 2026
|
|
🛑 N-nitroso Ticagrelor
|
|
32
|
4546
|
August 8, 2026
|
|
N Nitroso Tadalfil
|
|
19
|
1592
|
August 7, 2026
|
|
Nitrosamine Control Strategy for Products within the Scope of ICH S9
|
|
5
|
383
|
August 7, 2026
|
|
Differential Mutagenic Response of Rat Liver and Lung to Nicotine-Derived Nitrosamine Ketone (NNK)-Pub
|
|
0
|
122
|
August 5, 2026
|
|
Determination of Trace Nitrosamines in Plastic Pharmaceutical Packaging Materials
|
|
2
|
223
|
August 4, 2026
|
|
Nitrosamine risk assessment for short-term therapies: lifetime assumptions versus less-than-lifetime (LTL) exposure
|
|
2
|
246
|
August 4, 2026
|
|
🦺 A new Home, the same community!
|
|
38
|
919
|
August 3, 2026
|
|
🇺🇸 FDA updates 'estimated duration' dates on Recommended Interim AI limits
|
|
1
|
287
|
August 3, 2026
|
|
🇺🇸 FDA Control of Nitrosamine Impurities in Human Drugs revision2
|
|
63
|
7331
|
October 3, 2025
|
|
N-Nitroso meglumine
|
|
34
|
3227
|
August 1, 2026
|
|
N-Nitroso Abacavir Impurity possibility in physical state as standard
|
|
5
|
192
|
August 1, 2026
|
|
QSAR Toolbox - Free software. Any experience?
|
|
22
|
2761
|
July 31, 2026
|
|
Integrating nitrosamine theoretical formation into Translational Pharmaceutics: Mitigating risks during accelerated formulation development in early phase clinical studies-Pub
|
|
0
|
151
|
July 28, 2026
|
|
Nitrosamine Workshop, Hyderabad, August 19 & 20
|
|
3
|
403
|
July 27, 2026
|
|
N-Nitroso Desmethyl Tramadol - Standard
|
|
3
|
307
|
July 27, 2026
|
|
Nitrosamines: Mass Spectrometry-Based Analytical Procedures Criterias
|
|
12
|
4778
|
July 25, 2026
|
|
Complex versus simple N-nitrosamines: Comprehensive genotoxicity and in silico carcinogenicity assessment toward future testing paradigms -Pub
|
|
8
|
845
|
July 25, 2026
|
|
Which Molecule Is Involved in the Nitrosation Reaction of Pharmaceuticals: NO or NO 2 ? -Pub
|
|
3
|
317
|
July 24, 2026
|
|
CrN-coated punches and nitrosamine risk
|
|
0
|
110
|
July 23, 2026
|
|
AI limit for N-nitroso betahistine?
|
|
32
|
4877
|
July 23, 2026
|
|
Establishment of Limits in ppm (mg/kg) for Drug Products
|
|
2
|
295
|
July 22, 2026
|
|
MEGLUMINE (Methylglucamine)
|
|
31
|
4643
|
July 20, 2026
|
|
N-nitrosoproline
|
|
0
|
128
|
July 20, 2026
|
|
Determining Low PPB Levels of Nitrite in Polymeric Excipients
|
|
2
|
443
|
July 19, 2026
|